ArticleLangenbeck's archives of surgery2010
Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade.
Article in Langenbeck's archives of surgery, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Contemporary Approaches to Adrenocortical Carcinoma.Hematology/oncology clinics of North America · 2026Review
- A review of mitotane in the management of adrenocortical cancer.The oncologist · 2024Review
- Advances in translational research of the rare cancer type adrenocortical carcinoma.Nature reviews. Cancer · 2023Review
- Identification of Molecular Subtypes and Prognostic Characteristics of Adrenocortical Carcinoma Based on Unsupervised Clustering.International journal of molecular sciences · 2023Article
- Article
- A Revised Version of the TNM Classification Leads to Optimized Predictive Performance in Patients with Adrenocortical Carcinoma.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2023Article
- Article
- Prognostic Factors in Advanced Adrenocortical Carcinoma: Summary of a National Referral Center's 20 years of Experience.Journal of the Endocrine Society · 2022Article
- A Novel Predictive Model for Adrenocortical Carcinoma Based on Hypoxia- and Ferroptosis-Related Gene Expression.Frontiers in medicine · 2022Article
- Adjuvant therapy in adrenocortical carcinoma: prognostic factors and treatment options.Endocrine oncology (Bristol, England) · 2022Review
- Cumulative GRAS Score as a Predictor of Survival After Resection for Adrenocortical Carcinoma: Analysis From the U.S. Adrenocortical Carcinoma Database.Annals of surgical oncology · 2021Article
- Surgical Management of Adrenocortical Carcinoma: Current Highlights.Biomedicines · 2021Review
- Non-functioning adrenocortical carcinoma.Radiology case reports · 2021Article
- The Role of Immunohistochemical Markers for the Diagnosis and Prognosis of Adrenocortical Neoplasms.Journal of personalized medicine · 2021Article
- Adrenocortical carcinoma: current state of the art, ongoing controversies, and future directions in diagnosis and treatment.Therapeutic advances in chronic disease · 2021Review
- A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma.Investigational new drugs · 2020Article
- Intratumor heterogeneity of prognostic DNA-based molecular markers in adrenocortical carcinoma.Endocrine connections · 2020Article
- The clinical utility of 'GRAS' parameters in stage I-III adrenocortical carcinomas: long-term data from a high-volume institution.Endocrine · 2020Article
- Clinicopathological and Prognostic Characteristics of CD276 (B7-H3) Expression in Adrenocortical Carcinoma.Disease markers · 2020Article
- Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients.BMC cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeVarious staging systems for adrenocortical carcinoma (ACC) have been proposed. We hypothesized that incorporating tumor grade into the current European Network for the Study of Adrenal Tumors (ENSAT) staging system would improve the ability to more accurately predict time to recurrence and death.
methodsA retrospective review of patients included in the University of Michigan ACC database from 2005 to 2009 was done; and stage, tumor grade, time to recurrence, and death were recorded and analyzed using the Cox regression and Kaplan-Meier survival curves.
resultsNinety one patients had complete information for inclusion. The median follow-up was 24 months while the median time to recurrence was 4.1 months. There were 28 deaths; overall, tumor grade showed a significant difference in time to tumor recurrence (p = 0.011) and time to death (p = 0.004). Time to death among stage 2 patients separated into those with high- and low-grade tumors reached statistical significance (p = 0.05), and notable but not statistically significant differences were identified in all stages. Based on tumor grade and survival curves, modifications to the current ENSAT staging system were made.
conclusionTumor grade plays a significant role in the outcome of patients with ACC. High-grade tumors are associated with shorter disease-free intervals and shorter overall survival. The proposed modification of the ENSAT staging system allows for incorporation of tumor grade when predicting overall survival.
Indexed as
Identifiers
20694732What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.